{"id":34,"date":"2023-03-02T09:26:47","date_gmt":"2023-03-02T08:26:47","guid":{"rendered":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/?page_id=34"},"modified":"2026-07-02T08:52:18","modified_gmt":"2026-07-02T06:52:18","slug":"centre-regional-de-pharmacovigilance","status":"publish","type":"page","link":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/","title":{"rendered":"Centre r\u00e9gional de pharmacovigilance"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1677678988949{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb]\n

La pharmacovigilance a pour objet la surveillance, l\u2019\u00e9valuation, la pr\u00e9vention et la gestion du risque d\u2019effet ind\u00e9sirable<\/strong> r\u00e9sultant de l\u2019utilisation des m\u00e9dicaments et produits \u00e0 finalit\u00e9 sanitaire \u00e0 usage humain.<\/p>\n[\/vc_column_text][vc_column_text]\n

Le centre r\u00e9gional de pharmacovigilance (CRPV) de Poitiers contribue \u00e0 la protection des patients et \u00e0 la sant\u00e9 publique et effectue ses missions au niveau national et europ\u00e9en sous la coordination de l\u2019Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM).<\/p>\n[\/vc_column_text][vc_column_text]\n

Le CRPV de Poitiers est \u00e9galement membre du r\u00e9seau r\u00e9gional de vigilances et d\u2019appui de la Nouvelle-Aquitaine (RREVA-NA), pilot\u00e9 par l\u2019Agence r\u00e9gionale de sant\u00e9 (ARS) Nouvelle-Aquitaine.<\/p>\n[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-map-marker\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677678590078{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_column_text]\n

Il assure ses missions sur les d\u00e9partements de Charente (16), Charente-Maritime (17), Deux-S\u00e8vres (79), Vienne (86).<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-users\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677678607372{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Responsable du CRPV de Poitiers\u00a0<\/strong>: Dr Mah\u00e9 Julien
\nEquipe :<\/strong>\u00a0 Pr Pain, St\u00e9phanie, Dr Allouchery Marion, Dr Favreli\u00e8re Sylvie, Dr Mirfendereski Nassir, Mme Ennaciri Arka\u00efda<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_tta_accordion shape=\u00a0\u00bbsquare\u00a0\u00bb active_section=\u00a0\u00bb13″ no_fill=\u00a0\u00bbtrue\u00a0\u00bb collapsible_all=\u00a0\u00bbtrue\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbActivit\u00e9s\u00a0\u00bb tab_id=\u00a0\u00bb1677667701778-183ccba4-8256″][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-bar-chart\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677683757921{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_column_text]\n

Recueil et analyse des d\u00e9clarations d\u2019effets ind\u00e9sirables<\/strong> et d\u2019erreurs m\u00e9dicamenteuses signal\u00e9es par les professionnels de sant\u00e9 et les usagers et investigation du risque m\u00e9dicamenteux<\/p>\n[\/vc_column_text][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-handshake-o\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677683797563{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_column_text]\n

Aide au diagnostic<\/strong> et \u00e0 la gestion<\/strong> d\u2019une pathologie m\u00e9dicamenteuse, \u00e0 l\u2019\u00e9valuation du risque m\u00e9dicamenteux et \u00e0 la prescription adapt\u00e9e lors d\u2019une situation \u00e0 risque<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_column_text]\n

Aide et conseil<\/strong> aux prescripteurs<\/strong> pour la pr\u00e9vention du risque m\u00e9dicamenteux (m\u00e9dicaments et grossesse ; m\u00e9dicaments et allaitement ; erreurs m\u00e9dicamenteuses ; populations \u00e0 risque etc.)<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_column_text]\n

Expertise et appui<\/strong> en mati\u00e8re de pharmacovigilance, d\u2019information sur le m\u00e9dicament, de pr\u00e9vention du risque m\u00e9dicamenteux et de promotion du bon usage du m\u00e9dicament aupr\u00e8s des \u00e9tablissements de sant\u00e9 et des \u00e9tablissements et services m\u00e9dicosociaux de notre territoire, du directeur g\u00e9n\u00e9ral de l\u2019ARS, du directeur g\u00e9n\u00e9ral de l\u2019ANSM et de toute autre structure institutionnelle<\/p>\n[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-map-signs\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677683822081{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_column_text]\n

Animation territoriale, accompagnement et formation<\/strong> au sein de son territoire en mati\u00e8re de pharmacosurveillance, de risque m\u00e9dicamenteux et de sa pr\u00e9vention, et de promotion du bon usage du m\u00e9dicament<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_icon icon_fontawesome=\u00a0\u00bbfa fa-flask\u00a0\u00bb color=\u00a0\u00bbcustom\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1677683831753{margin-bottom: 5px !important;border-bottom-width: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb custom_color=\u00a0\u00bb#23b093″][vc_column_text]\n

Contribution au progr\u00e8s scientifique par la recherche<\/strong> dans le domaine des risques li\u00e9s \u00e0 l\u2019utilisation des m\u00e9dicament<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbD\u00e9clarer un effet ind\u00e9sirable\u00a0\u00bb tab_id=\u00a0\u00bb1677667701797-5b72ea78-95e1″][vc_column_text]\n

Vous pouvez contacter le CRPV de Poitiers par t\u00e9l\u00e9phone au 05 49 44 38 36<\/strong> durant les heures de permanence ou par mail \u00e0 pharmaco.clin@chu-poitiers.fr<\/a> pour d\u00e9clarer un effet ind\u00e9sirable ou pour toute demande de renseignement en lien avec nos activit\u00e9s.<\/p>\n[\/vc_column_text][vc_column_text]\n

Les professionnels de sant\u00e9 ou les usagers peuvent signaler tout effet ind\u00e9sirable sur le site signalement-sante.gouv.fr.<\/p>\n[\/vc_column_text][vc_btn title=\u00a0\u00bbAcc\u00e9der \u00e0 la plateforme\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fsignalement.social-sante.gouv.fr%2Fpsig_ihm_utilisateurs%2Findex.html%23%2Faccueil||target:%20_blank|\u00a0\u00bb][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbBulletins d’information\u00a0\u00bb tab_id=\u00a0\u00bb1677667738153-1fcbbb29-cba2″][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b018 – Et\u00e9 2026″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2026%2F07%2Fbulletin-information-NA-n18-special-ete-2026-VF-2026.06.23.pdf|target:_blank\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Sommaire :
\n<\/strong>Num\u00e9ro sp\u00e9cial BENZODIAZEPINES.
\nBenzodiaz\u00e9pines : quand tous les vigilants ont quelque chose \u00e0 dire ;
\nD\u00e9prescrire les benzodiaz\u00e9pines ;
\nR\u00e9actions paradoxales aux benzodiaz\u00e9pines : un risque rare mais \u00e0 ne pas m\u00e9conna\u00eetre ;
\nBenzodiaz\u00e9pines et conduite automobile ;
\nLes benzodiaz\u00e9pines pendant la grossesse et l\u2019allaitement ;
\nDonn\u00e9es de toxicovigilance pour les expositions aux benzodiaz\u00e9pines chez les moins de 15 ans en Nouvelle-Aquitaine entre 2020 et 2025 ;
\nM\u00e9susage et abus des benzodiaz\u00e9pines : le point de vue de l\u2019addictovigilance.<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b017 – Mars 2026″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2026%2F04%2Fbulletin-information-NA-n17-mars-2026-VF-2026.03.24.pdf|target:_blank\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Sommaire :
\n<\/strong>M\u00e9dicaments psychotropes et chirurgie bariatrique ;
\nM\u00e9dicaments abaissant le seuil \u00e9pileptog\u00e8ne ;
\nSurvenue de prurit apr\u00e8s arr\u00eat de c\u00e9tirizine ;
\nOn a lu pour vous : \u00ab R\u00e9viser la pharmacologie, en BD \u00bb<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b016 – Octobre 2025″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2025%2F11%2Fbulletin-information-NA-n16-octobre-2025-VF-2025.10.17.pdf|target:_blank\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Sommaire :
\n<\/strong>Allergie crois\u00e9e entre sulfamides antibact\u00e9riens et non antibact\u00e9riens ;
\nLithium et rein ;
\nAngi\u0153d\u00e8mes bradykiniques : les sartans hors de cause ;
\nOn a lu pour vous : \u00ab Pharmacologix \u00bb ;
\nParac\u00e9tamol et grossesse : La science contre la rumeur !<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b015 – Mai 2025″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2025%2F06%2Fbulletin-information-NA-n15-mai-2025-VF-2025.05.21.pdf|target:_blank\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Sommaire :
\n<\/strong>Le syndrome de vasoconstriction c\u00e9r\u00e9brale r\u00e9versible d\u2019origine m\u00e9dicamenteuse ;
\nThiocolchicoside : renforcement des pr\u00e9cautions en lien avec un risque g\u00e9notoxique ;
\nEryth\u00e8me pigment\u00e9 fixe \u00e0 la doxycycline ;
\nAntid\u00e9presseurs et dysfonctions sexuelles ;
\nToxidermies sous lamotrigine ;
\nHypersialorrh\u00e9e sous clozapine ;<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b014 – Janvier 2025″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2025%2F02%2Fbulletin-information-NA-n14-janvier-2025-VF-2025.01.23.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]\n

Sommaire :<\/strong>
\nMucites orales : pr\u00e9vention et gestion ;
\nInsuffisance surr\u00e9nale induite par les opio\u00efdes ;
\nRecommandations du r\u00e9seau francophone de Pharmacog\u00e9n\u00e9tique pour l\u2019utilisation du mavacamten ;
\nFardeau \u00e9conomique des hospitalisations pour effet ind\u00e9sirable m\u00e9dicamenteux en France ;
\nM\u00e9thotrexate et atteinte h\u00e9matologique ;
\nOn a lu pour vous \u00ab\u00a0Que choisir : M\u00e9dicaments p\u00e9rim\u00e9s, encore actifs longtemps\u00a0\u00bb<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b013 – Octobre 2024″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2024%2F12%2Fbulletin-information-Nouvelle-aquitaine-Octobre-2024.pdf|target:_blank\u00a0\u00bb][vc_column_text]\n

Sommaire :
\n<\/strong>Pipettes doseuses ou seringues doseuses pour une administration orale en p\u00e9diatrie\u00a0;
\nPADCEV et effets ind\u00e9sirables cutan\u00e9s\u00a0;
\nCabergoline\u00a0: au-del\u00e0 de la lactation, un irsque vasculaire c\u00e9r\u00e9bral \u00e0 ne pas m\u00e9connaitre\u00a0;
\nCas clinique : colite et inhibiteurs de points de contr\u00f4le immunitaires ;
\nLes erreurs d\u2019utilisation de la m\u00e9thadone ajout\u00e9es \u00e0 la liste des nerver events ;
\nOn a lu pour vous : \u00ab Marion \u00bb de Christian Binet et Marion Larat.<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b012 – Mai 2024″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2024%2F12%2Fbulletin-information-NA-n12-mai-2024-VF-2024.05.22.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Alerte sur les infections bact\u00e9riennes invasives sous Anti-Inflammatoires Non St\u00e9ro\u00efdiens (AINS) ;
\nAttention \u00e0 la prescription des H\u00e9parines de Bas Poids Mol\u00e9culaires (HBPM), notamment INNOHEP ;
\nLes CAR-T cells : traitement novateur et profil de s\u00e9curit\u00e9 ;
\nSyndrome de perfusion du propofol : quelques rappels ;
\nTramadol : nouvelles pr\u00e9sentations avec 10 ou 15 comprim\u00e9s ou g\u00e9lules ;
\nEncore des prescriptions de SELINCRO\u00ae chez des patients sous METHADONE ou SUBUTEX\u00ae.<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b011 – Janvier 2024″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2024%2F01%2Fbulletin-information-NA-janvier-2024-VF-2024.01.24.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire :
\n<\/strong>Colchicine dans la goutte : nouveau sch\u00e9ma
\nFentanyl : risques d\u2019erreurs et m\u00e9susage
\nMians\u00e9rine et troubles du sommeil chez les personnes \u00e2g\u00e9es
\nLes fluoroquinolones doivent \u00eatre \u00e9vit\u00e9es en pratique
\nLamotrigine : rappel du bon usage
\nLe circuit du diagnostic d\u2019effet ind\u00e9sirable
\nTroubles digestifs graves sous antipsychotiques
\nOn a lu pour vous \u00ab Pilules Roses, de l\u2019ignorance en m\u00e9decine \u00bb<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b010 – Octobre 2023″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2023%2F12%2Fbulletin-information-NA-n10-octobre-2023-VF-2023.10.24.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire\u00a0:
\n<\/strong>Daridorexant (QUVIVIQ) : est-ce une r\u00e9volution dans l\u2019insomnie ?
\nLa cascade th\u00e9rapeutique
\nM\u00e9dicaments p\u00e9diatriques contenant de l\u2019\u00e9thanol
\nLe PharmacoQuiz d\u00e9sormais sur Instagram\u00ae
\nEffets ind\u00e9sirables psychiatriques des nouveaux traitements de la mucoviscidose : risque suicidaire
\nL\u2019\u00e9nigme de la pharmacovigilance
\nCoca\u00efne en Nouvelle-Aquitaine.<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b09 – Juin 2023″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2023%2F12%2Fbulletin-information-juin-2023-VF-2023.06.20.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire\u00a0:
\n<\/strong>Usage des alpha-bloquants chez la femme
\nS\u00e9rotonine et \u0153il
\nLa M\u00e9thadone : un produit pas banal
\nVous avez dit \u00ab m\u00e9dicaments \u00e0 risque \u00bb ?
\nNeuropathie induite par le traitement du diab\u00e8te
\nAcidoc\u00e9tose au cours de traitement par les inhibiteurs de SGTL2
\nEnigme de pharmacovigilance
\nOzempic et m\u00e9susage m\u00e9dicamenteux : information ANSM.<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b08 – Mars 2023″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2023%2F03%2Fbulletin-information-8-mars-2023.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire\u00a0:
\n<\/strong>Ruptures de stock de m\u00e9dicaments
\nUtilisation et s\u00e9curit\u00e9 des m\u00e9dicaments inhibiteurs de la pompe \u00e0 protons
\nProduits de contraste iod\u00e9s et r\u00e9actions d\u2019hypersensibilit\u00e9 retard\u00e9e Cod\u00e9ine-ibuprof\u00e8ne : abus et de d\u00e9pendance
\nPlace de la morphine et de l\u2019oxycodone dans la prise en charge de la douleur chez le sujet \u00e2g\u00e9
\nD\u00e9tournement du m\u00e9thylph\u00e9nidate en Aquitaine
\n\u00c9nigme de la pharmacovigilance.<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b07 – Novembre 2022″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2023%2F03%2Fbulletin-information-NA-novembre-2022.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire\u00a0:<\/strong>
\nAttention \u00e0 l\u2019utilisation prolong\u00e9e des IPP
\nPip\u00e9racilline, pip\u00e9racilline\/tazobactam et LHH ou SAM
\nPermanganate de potassium et risque de br\u00fblure cutan\u00e9e grave
\nIATROSTAT : \u00e9tude sur les hospitalisations pour EI m\u00e9dicamenteux
\nPancr\u00e9atite aig\u00fce m\u00e9dicamenteuse : un diagnostic d\u2019exclusion.<\/p>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbN\u00b06 – Juin 2022″ style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb i_icon_fontawesome=\u00a0\u00bbfa fa-solid fa-newspaper\u00a0\u00bb css=\u00a0\u00bb\u00a0\u00bb add_icon=\u00a0\u00bbtrue\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Fwww.chu-poitiers.fr%2Fspecialites%2Fpharmacologie-clinique-vigilances%2Fwp-content%2Fuploads%2Fsites%2F85%2F2023%2F03%2Fbulletin-information-NA-juin-2022.pdf||target:%20_blank|\u00a0\u00bb][vc_column_text]\n

Sommaire :<\/strong>
\nQuoi de neuf dans le calendrier vaccinal ?
\nNirmaltr\u00e9vir\/ritonavir (PAXLOVID\u00ae)
\nREMEDI[e]S : un nouvel outil fran\u00e7ais de prescription ou d\u00e9prescription
\nDe nouvelles recommandations sur l\u2019apport de vitamine D en p\u00e9diatrie
\nPoint de pharmacovigilance pour les inhibiteurs de Janus Kinase.<\/p>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbRessources\u00a0\u00bb tab_id=\u00a0\u00bb1677667748290-2339e5f1-2377″][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbR\u00e9seau fran\u00e7ais des centres r\u00e9gionaux de pharmacovigilance\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fwww.rfcrpv.fr%2Fmissions%2F||target:%20_blank|\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2″][vc_btn title=\u00a0\u00bbBonnes pratiques de pharmacovigilance\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbsquare\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:https%3A%2F%2Fansm.sante.fr%2Fdocuments%2Freference%2Fbonnes-pratiques-de-pharmacovigilance||target:%20_blank|\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1677678988949{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] La pharmacovigilance a pour objet la surveillance, l\u2019\u00e9valuation, la pr\u00e9vention et la gestion du risque d\u2019effet ind\u00e9sirable r\u00e9sultant de l\u2019utilisation des m\u00e9dicaments et produits \u00e0 finalit\u00e9 sanitaire \u00e0 usage humain. [\/vc_column_text][vc_column_text] Le centre r\u00e9gional de […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-34","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nCentre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Centre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1677678988949{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] La pharmacovigilance a pour objet la surveillance, l\u2019\u00e9valuation, la pr\u00e9vention et la gestion du risque d\u2019effet ind\u00e9sirable r\u00e9sultant de l\u2019utilisation des m\u00e9dicaments et produits \u00e0 finalit\u00e9 sanitaire \u00e0 usage humain. [\/vc_column_text][vc_column_text] Le centre r\u00e9gional de […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmacologie clinique et vigilances\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-02T06:52:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/centre-regional-de-pharmacovigilance\\\/\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/centre-regional-de-pharmacovigilance\\\/\",\"name\":\"Centre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/#website\"},\"datePublished\":\"2023-03-02T08:26:47+00:00\",\"dateModified\":\"2026-07-02T06:52:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/centre-regional-de-pharmacovigilance\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/centre-regional-de-pharmacovigilance\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/centre-regional-de-pharmacovigilance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"CHU de Poitiers\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Services\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/services\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pharmacologie clinique et vigilances\",\"item\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Centre r\u00e9gional de pharmacovigilance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/#website\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/\",\"name\":\"Pharmacologie clinique et vigilances\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/specialites\\\/pharmacologie-clinique-vigilances\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Centre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/","og_locale":"fr_FR","og_type":"article","og_title":"Centre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances","og_description":"[vc_row][vc_column][vc_column_text css=\u00a0\u00bb.vc_custom_1677678988949{margin-top: 10px !important;margin-right: 10px !important;margin-bottom: 10px !important;margin-left: 10px !important;padding-top: 10px !important;padding-right: 10px !important;padding-bottom: 10px !important;padding-left: 10px !important;background-color: #ecf2f4 !important;}\u00a0\u00bb] La pharmacovigilance a pour objet la surveillance, l\u2019\u00e9valuation, la pr\u00e9vention et la gestion du risque d\u2019effet ind\u00e9sirable r\u00e9sultant de l\u2019utilisation des m\u00e9dicaments et produits \u00e0 finalit\u00e9 sanitaire \u00e0 usage humain. [\/vc_column_text][vc_column_text] Le centre r\u00e9gional de […]","og_url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/","og_site_name":"Pharmacologie clinique et vigilances","article_modified_time":"2026-07-02T06:52:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/","url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/","name":"Centre r\u00e9gional de pharmacovigilance - Pharmacologie clinique et vigilances","isPartOf":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/#website"},"datePublished":"2023-03-02T08:26:47+00:00","dateModified":"2026-07-02T06:52:18+00:00","breadcrumb":{"@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/centre-regional-de-pharmacovigilance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"CHU de Poitiers","item":"https:\/\/www.chu-poitiers.fr\/"},{"@type":"ListItem","position":2,"name":"Services","item":"https:\/\/www.chu-poitiers.fr\/services\/"},{"@type":"ListItem","position":3,"name":"Pharmacologie clinique et vigilances","item":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/"},{"@type":"ListItem","position":4,"name":"Centre r\u00e9gional de pharmacovigilance"}]},{"@type":"WebSite","@id":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/#website","url":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/","name":"Pharmacologie clinique et vigilances","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/34","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/comments?post=34"}],"version-history":[{"count":5,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/34\/revisions"}],"predecessor-version":[{"id":379,"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/pages\/34\/revisions\/379"}],"wp:attachment":[{"href":"https:\/\/www.chu-poitiers.fr\/specialites\/pharmacologie-clinique-vigilances\/wp-json\/wp\/v2\/media?parent=34"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}